AIMS: Few prognostic models in heart failure have been developed in typically elderly patients treated withmodern pharmacological therapy and even fewer included simple biochemical tests (such as creatinine), new biomarkers (such as natriuretic peptides), or, especially, both. In addition, most models have been developed for the single outcome of all-cause mortality. METHODS AND RESULTS: We built a series of models for nine different fatal and non-fatal outcomes. For each outcome, a model was first built using demographic and clinical variables (Step 1), then with the addition of biochemical measures (serum creatinine, alanine aminotransferase, creatine kinase, thyrotrophin, apolipoproteins A-1 and B, and triglycerides) (Step 2) and finally with the incorporation of high-sensitivity C-reactive protein (hsCRP) and N-terminal pro B-type natriuretic peptide (NT-proBNP). Ranked according to the Wald chi(2) value, age (56), ejection fraction (44), and body mass index (42) were most predictive of all-cause mortality in Step 1 (total model chi(2) 343). Creatinine was the most powerful predictor at Step 2 (48) and ApoA-1 ranked fifth (25), with the overall chi(2) increasing to 440. Log NT-proBNP (167) was the most powerful of the 14 independently predictive variables identified at Step 3 and the overall chi(2) increased to 600. NT-proBNP was the most powerful predictor of each other outcome. hsCRP was not a predictor of all-cause mortality but did predict the composite atherothrombotic outcome. CONCLUSION: Of the two new biomarkers studied in prognostic models in heart failure, NT-proBNP, but not hsCRP, added substantial and independent predictive information, for a range of clinical outcomes, to that provided by simple demographic, clinical, and biochemical measures. ApoA-1 was more predictive than LDL or HDL.
RCT Entities:
AIMS: Few prognostic models in heart failure have been developed in typically elderly patients treated with modern pharmacological therapy and even fewer included simple biochemical tests (such as creatinine), new biomarkers (such as natriuretic peptides), or, especially, both. In addition, most models have been developed for the single outcome of all-cause mortality. METHODS AND RESULTS: We built a series of models for nine different fatal and non-fatal outcomes. For each outcome, a model was first built using demographic and clinical variables (Step 1), then with the addition of biochemical measures (serum creatinine, alanine aminotransferase, creatine kinase, thyrotrophin, apolipoproteins A-1 and B, and triglycerides) (Step 2) and finally with the incorporation of high-sensitivity C-reactive protein (hsCRP) and N-terminal pro B-type natriuretic peptide (NT-proBNP). Ranked according to the Wald chi(2) value, age (56), ejection fraction (44), and body mass index (42) were most predictive of all-cause mortality in Step 1 (total model chi(2) 343). Creatinine was the most powerful predictor at Step 2 (48) and ApoA-1 ranked fifth (25), with the overall chi(2) increasing to 440. Log NT-proBNP (167) was the most powerful of the 14 independently predictive variables identified at Step 3 and the overall chi(2) increased to 600. NT-proBNP was the most powerful predictor of each other outcome. hsCRP was not a predictor of all-cause mortality but did predict the composite atherothrombotic outcome. CONCLUSION: Of the two new biomarkers studied in prognostic models in heart failure, NT-proBNP, but not hsCRP, added substantial and independent predictive information, for a range of clinical outcomes, to that provided by simple demographic, clinical, and biochemical measures. ApoA-1 was more predictive than LDL or HDL.
Authors: Inder S Anand; Lloyd D Fisher; Yann-Tong Chiang; Roberto Latini; Serge Masson; Aldo P Maggioni; Robert D Glazer; Gianni Tognoni; Jay N Cohn Journal: Circulation Date: 2003-03-11 Impact factor: 29.690
Authors: Mathias Rauchhaus; Andrew L Clark; Wolfram Doehner; Constantinos Davos; Aidan Bolger; Rakesh Sharma; Andrew J S Coats; Stefan D Anker Journal: J Am Coll Cardiol Date: 2003-12-03 Impact factor: 24.094
Authors: Mark T Kearney; Keith A A Fox; Amanda J Lee; Robin J Prescott; Ajay M Shah; Philip D Batin; Wazir Baig; Stephen Lindsay; Timothy S Callahan; William E Shell; Dwain L Eckberg; Azfar G Zaman; Simon Williams; James M M Neilson; James Nolan Journal: J Am Coll Cardiol Date: 2002-11-20 Impact factor: 24.094
Authors: Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Inder Anand; John J V McMurray; James Whitmore; Marshelle Warren; Anh Pham; Mark A McCamish; Paul B J Burton Journal: Circulation Date: 2004-06-21 Impact factor: 29.690
Authors: Andrew C Don-Wauchope; Pasqualina L Santaguida; Mark Oremus; Robert McKelvie; Usman Ali; Judy A Brown; Amy Bustamam; Nazmul Sohel; Stephen A Hill; Ronald A Booth; Cynthia Balion; Parminder Raina Journal: Heart Fail Rev Date: 2014-08 Impact factor: 4.214
Authors: Anne B Taegtmeyer; Jane B Breen; John Smith; Paula Rogers; Gerd A Kullak-Ublick; Magdi H Yacoub; Nicholas R Banner; Paul J R Barton Journal: J Cardiovasc Transl Res Date: 2011-03-29 Impact factor: 4.132
Authors: Christopher M O'Connor; David J Whellan; Daniel Wojdyla; Eric Leifer; Robert M Clare; Stephen J Ellis; Lawrence J Fine; Jerome L Fleg; Faiez Zannad; Steven J Keteyian; Dalane W Kitzman; William E Kraus; David Rendall; Ileana L Piña; Lawton S Cooper; Mona Fiuzat; Kerry L Lee Journal: Circ Heart Fail Date: 2011-11-23 Impact factor: 8.790
Authors: Paula K Lorgelly; Andrew H Briggs; Hans Wedel; Peter Dunselman; Ake Hjalmarson; John Kjekshus; Finn Waagstein; John Wikstrand; András Jánosi; Dirk J van Veldhuisen; Vivencio Barrios; Cândida Fonseca; John J V McMurray Journal: Eur J Heart Fail Date: 2010-01 Impact factor: 15.534